DGS Capital Management LLC Has $221,000 Stock Position in Stryker Co. (NYSE:SYK)

DGS Capital Management LLC cut its holdings in shares of Stryker Co. (NYSE:SYK) by 4.4% in the fourth quarter, HoldingsChannel reports. The fund owned 614 shares of the medical technology company’s stock after selling 28 shares during the quarter. DGS Capital Management LLC’s holdings in Stryker were worth $221,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Stryker by 9.7% during the 2nd quarter. AQR Capital Management LLC now owns 125,333 shares of the medical technology company’s stock valued at $42,485,000 after buying an additional 11,075 shares during the period. Scientech Research LLC raised its holdings in shares of Stryker by 46.3% during the second quarter. Scientech Research LLC now owns 1,527 shares of the medical technology company’s stock worth $520,000 after acquiring an additional 483 shares in the last quarter. Oliver Lagore Vanvalin Investment Group boosted its position in Stryker by 14.4% during the second quarter. Oliver Lagore Vanvalin Investment Group now owns 2,041 shares of the medical technology company’s stock valued at $694,000 after purchasing an additional 257 shares during the last quarter. Driehaus Capital Management LLC increased its position in Stryker by 73.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,107 shares of the medical technology company’s stock worth $377,000 after purchasing an additional 470 shares during the last quarter. Finally, Ascent Group LLC raised its stake in shares of Stryker by 4.4% during the 2nd quarter. Ascent Group LLC now owns 3,790 shares of the medical technology company’s stock worth $1,290,000 after purchasing an additional 159 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.1 %

Shares of SYK opened at $394.08 on Friday. The stock’s 50-day moving average price is $376.11 and its 200 day moving average price is $360.81. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12-month low of $307.23 and a 12-month high of $398.20. The firm has a market capitalization of $150.23 billion, a price-to-earnings ratio of 42.24, a P/E/G ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker’s dividend payout ratio (DPR) is presently 36.01%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SYK. BTIG Research raised their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their price objective on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. increased their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Citigroup boosted their price target on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Robert W. Baird increased their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Activity

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.